EX1 Stock Overview
Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Exopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.011 |
| 52 Week High | AU$0.079 |
| 52 Week Low | AU$0.008 |
| Beta | 1.24 |
| 1 Month Change | 0% |
| 3 Month Change | 10.00% |
| 1 Year Change | -81.67% |
| 3 Year Change | -98.07% |
| 5 Year Change | -97.68% |
| Change since IPO | -97.88% |
Recent News & Updates
Recent updates
Will Exopharm (ASX:EX1) Spend Its Cash Wisely?
May 27
Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Oct 20Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Jul 02Is Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?
Apr 03Shareholders Are Thrilled That The Exopharm (ASX:EX1) Share Price Increased 188%
Feb 09
Shareholder Returns
| EX1 | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -2.7% |
| 1Y | -81.7% | 3.1% | 6.5% |
Return vs Industry: EX1 underperformed the Australian Biotechs industry which returned 10% over the past year.
Return vs Market: EX1 underperformed the Australian Market which returned 9.6% over the past year.
Price Volatility
| EX1 volatility | |
|---|---|
| EX1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: EX1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EX1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 50 | Ian Dixon | exopharm.com |
Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company’s technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine.
Exopharm Limited Fundamentals Summary
| EX1 fundamental statistics | |
|---|---|
| Market cap | AU$4.83m |
| Earnings (TTM) | -AU$7.13m |
| Revenue (TTM) | AU$3.39m |
1.4x
P/S Ratio-0.7x
P/E RatioIs EX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EX1 income statement (TTM) | |
|---|---|
| Revenue | AU$3.39m |
| Cost of Revenue | AU$3.36m |
| Gross Profit | AU$28.17k |
| Other Expenses | AU$7.16m |
| Earnings | -AU$7.13m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 0.83% |
| Net Profit Margin | -210.14% |
| Debt/Equity Ratio | 37.2% |
How did EX1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/12/30 10:10 |
| End of Day Share Price | 2023/10/02 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Exopharm Limited is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|